S

Sonnet BioTherapeutics Holdings
D

SONN

1.39000
USD
-0.04
(-2.80%)
Market Closed
Volume
15,579
EPS
-1
Div Yield
-
P/E
-0
Market Cap
4,261,324
Related Instruments
    ABT
    ABT
    1.785
    (1.34%)
    134.950 USD
    D
    DGX
    0.115
    (0.07%)
    172.290 USD
    H
    HOLX
    0.180
    (0.28%)
    64.510 USD
    IDXX
    IDXX
    -0.33
    (-0.07%)
    452.66 USD
    P
    PACB
    -0.11000
    (-6.71%)
    1.53000 USD
    T
    TMDX
    -3.591
    (-4.76%)
    71.869 USD
    TMO
    TMO
    -5.71
    (-1.06%)
    532.28 USD
    V
    VEEV
    -2.960
    (-1.29%)
    225.900 USD
    More
News

Title: Sonnet BioTherapeutics Holdings Inc

Sector: Healthcare
Industry: Biotechnology
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.